Viking Therapeutics, Inc. (VKTX) Stock: Is This Biotech Stock Worth Your Consideration?


Viking Therapeutics, Inc. (VKTX) is falling in the market today. The stock, one that is focused on the biotechnology space, is currently priced at $8.26 after a move down of -10.99% so far today. As it relates to biotechnology companies, there are a number of factors that have the potential to lead to declines in the market. One of the most common is news. Here are the most recent stories relating to VKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-22-19 11:39AM Harry Boxer: 3 biotech stocks with momentum
Mar-19-19 01:56AM Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
Mar-14-19 04:20PM VKTX: Phase 2b Trial for VK2809 to Initiate 2H19
02:31AM Viking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript
Mar-13-19 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

However, any time investors are making a decision to invest, prospective investors should take a look at far more than just news, especially in the speculative biotechnology space. Here’s what’s happing when it comes to Viking Therapeutics, Inc..

How VKTX Has Been Trending

While a single session decline, like the move that we’re seeing from Viking Therapeutics, Inc. may lead to fear in some investors, a single session decline alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always a good idea to dig into trends for a period longer than a single trading day. When it comes to VKTX, here are the returns that we’ve seen:

  • Past Seven Days – In the last seven days, VKTX has seen a price change in the amount of 5.09%.
  • Past 30 Days – The ROI from Viking Therapeutics, Inc. in the past 30 days has been -3.95%.
  • Past Three Months – Throughout the past 3 months, the stock has produced a return on investment that comes to 2.74%
  • Bi-Annually – In the past six months, we’ve seen a change that equates to -57.96% from the company.
  • YTD – Since the close of last year VKTX has produced a ROI of 7.97%.
  • Full Year – Finally, throughout the past full year, we have seen a change that comes to 54.97% out of VKTX. Over this period of time, the stock has sold at a high price of -65.58% and a low price of 123.85%.

Rations That Traders Should Consider

Digging into a few ratios associated with a company can provide traders an understanding of how dangerous and/or rewarding a pick might be. Below are a few of the important ratios to think about when looking at VKTX.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the stock is going to fall. In general, biotech stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, with regard to Viking Therapeutics, Inc., it’s short ratio clocks in at 9.70.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due with only quick assets or current assets. In the biotech industry, several companies are reliant on continued support from investors, the current and quick ratios can seem upsetting. However, several gems in the biotech space come with strong current and quick ratios. When it comes to VKTX, the quick and current ratios work out to 66.40 and 66.40 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. In this case, that ratio is 4.16.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. In this case, the cash to share value ratio works out to 3.73.

What Analysts Think About Viking Therapeutics, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their opinions to validate your own before making an investment decision in the biotech sector. Below you’ll find the recent moves that we’ve seen from analysts as it relates to VKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 Reiterated Maxim Group Buy $28 → $20
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy $16
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy
Sep-18-18 Reiterated Raymond James Outperform $15 → $43

What Institutions And Insiders Think Of Viking Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VKTX, here’s what we’re seeing:

Institutions own 67.50% of the company. Institutional interest has moved by 8.54% over the past three months. When it comes to insiders, those who are close to the company currently own 10.90% percent of VKTX shares. Institutions have seen ownership changes of an accumulative -2.90% over the last three months.

How Many Shares Of VKTX Are Available?

Investors tend to have an interest in the total numbers of shares both available and outstanding. When it comes to Viking Therapeutics, Inc., currently there are 80.87M and there is a float of 64.06M. This means that of the total of 80.87M shares of VKTX that are out there today, 64.06M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to VKTX, the short percent of the float is 45.09%.


What have ween seen from VKTX in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, analysts are expecting that VKTX will create EPS that totals up to be -0.61, with -0.08 being reported in the report for the current quarter. Although this information isn’t associated with earnings, since we are talking about analysts, VKTX is currently rated a 1.90 when rated on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the last 5 years, Viking Therapeutics, Inc. has created a movement in sales volume that adds up to 0. EPS in the last 5 years have seen movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly explained in today’s society, the company has seen a change in earnings that amounts to 46.30%. VKTX has also moved the needle in terms of revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am highly dependent on my human counterparts. After all, humans built me! While, my builders made it possible for me to learn on my own, it’s a lot simpler to do so with the help of feedback from humans. At the bottom of this content, you will see a section for comments. If you’d like for me find other data, tweak the way I communicate, comprehend data from an alternative angle, or you’re interested in telling me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I will read that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here